These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 14655309)

  • 1. Safety evaluation of the use of femural percutaneous closure systems with simultaneous use of abciximab.
    Timóteo AT; Batista J; Almeida M; Machado FP; Palos JL; Silva JA; Seabra-Gomes R
    Rev Port Cardiol; 2003 Sep; 22(9):1063-72. PubMed ID: 14655309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Femoral arterial puncture management after percutaneous coronary procedures: a comparison of clinical outcomes and patient satisfaction between manual compression and two different vascular closure devices.
    Duffin DC; Muhlestein JB; Allisson SB; Horne BD; Fowles RE; Sorensen SG; Revenaugh JR; Bair TL; Lappe DL
    J Invasive Cardiol; 2001 May; 13(5):354-62. PubMed ID: 11385148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring abciximab (ReoPro).
    Chamberlin JR; Lardi AB; McKeever LS; Wang MH; Ramadurai G; Grunenwald P; Towne WP; Grassman ED; Leya FS; Lewis BE; Stein LH
    Catheter Cardiovasc Interv; 1999 Jun; 47(2):143-7; discussion 148. PubMed ID: 10376492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
    Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of transradial vs. transfemoral approach in the treatment of acute myocardial infarction with primary angioplasty and abciximab.
    Philippe F; Larrazet F; Meziane T; Dibie A
    Catheter Cardiovasc Interv; 2004 Jan; 61(1):67-73. PubMed ID: 14696162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular complications and clinical outcome after coronary angioplasty with platelet IIb/IIIa receptor blockade. Comparison of transradial vs transfemoral arterial access.
    Choussat R; Black A; Bossi I; Fajadet J; Marco J
    Eur Heart J; 2000 Apr; 21(8):662-7. PubMed ID: 10731404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularization.
    Applegate RJ; Grabarczyk MA; Little WC; Craven T; Walkup M; Kahl FR; Braden GA; Rankin KM; Kutcher MA
    J Am Coll Cardiol; 2002 Jul; 40(1):78-83. PubMed ID: 12103259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices.
    Assali AR; Sdringola S; Moustapha A; Ghani M; Salloum J; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Catheter Cardiovasc Interv; 2003 Jan; 58(1):1-5. PubMed ID: 12508187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of abciximab in coronary angioplasty--an Asian centre's experience.
    Tan HC; Lim YT; Lim TT; Cheng A; Chia BL
    Singapore Med J; 2000 Feb; 41(2):69-73. PubMed ID: 11063206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
    Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
    Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transradial approach in patients with ST-elevation myocardial infarction treated with abciximab results in fewer bleeding complications: data from EUROTRANSFER registry.
    Siudak Z; Zawislak B; Dziewierz A; Rakowski T; Jakala J; Bartus S; Noworolnik B; Zasada W; Dubiel JS; Dudek D
    Coron Artery Dis; 2010 Aug; 21(5):292-7. PubMed ID: 20453640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective randomised study to evaluate effectiveness of distal embolic protection compared to abciximab administration in reduction of microembolic complications of primary coronary angioplasty.
    Ochała A; Smolka G; Wojakowski W; Gabrylewicz B; Garbocz P; Tendera M
    Kardiol Pol; 2007 Jun; 65(6):672-80; discussion 681-3. PubMed ID: 17629829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the glycoprotein IIb/IIIa antagonist abciximab during percutaneous coronary interventions (PCI) in clinical practice at a single high-volume center.
    Zahn R; Fraiture B; Siegler KE; Schneider S; Gitt AK; Seidl K; Gandjour A; Wendland G; Vogt S; Lauterbach KW; Senges J
    Z Kardiol; 2003 Jun; 92(6):438-44. PubMed ID: 12819992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.